Pharmaceutical development of IPI-504, an Hsp90 inhibitor and clinical candidate for the treatment of cancer

MLA

John Lee, et al. “Pharmaceutical Development of IPI-504, an Hsp90 Inhibitor and Clinical Candidate for the Treatment of Cancer.” Drug Development Research, vol. 71, Oct. 2010, pp. 429–38. EBSCOhost, https://doi.org/10.1002/ddr.20383.

APA

John Lee, Roger H. Pak, Louis Grenier, Vince Ammoscato, Michael Curtis, Kaiming Li, John Henderson, Matthew Campbell, Denise Mayes, Jason Kropp, Natalie Goltz, Bennett Carter, Johan Sebastian Basuki, Bradley Maurer, Gary Baker, James R. Wright, David Rusch, Rebecca Ahn, Brian C. Austad, … Brendan Arsenault. (2010). Pharmaceutical development of IPI-504, an Hsp90 inhibitor and clinical candidate for the treatment of cancer. Drug Development Research, 71, 429–438. https://doi.org/10.1002/ddr.20383

Chicago

John Lee, Roger H. Pak, Louis Grenier, Vince Ammoscato, Michael Curtis, Kaiming Li, John Henderson, et al. 2010. “Pharmaceutical Development of IPI-504, an Hsp90 Inhibitor and Clinical Candidate for the Treatment of Cancer.” Drug Development Research 71 (October): 429–38. doi:10.1002/ddr.20383.